Skip to main content

Table 2 Adverse events, according to CTC grades, occurring in >10% of patients

From: Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer

Toxicity Patients Grade 1 Grade 2 Grade 3 Grade 4
n n (%) n (%) n (%) n (%)
Alopecia 30 18 (60.0) 11 (36.7) 0 0
Fatigue and asthenia 30 14 (46.7) 14 (46.7) 0 0
Sensory neuropathy 30 9 (30.0) 4 (13.3) 0 0
Edema 30 16 (53.3) 0 0 0
Nausea and vomiting 30 10 (30.0) 0 0 0
Diarrhea 30 6 (20.0) 1 (3.3) 0 0
Constipation 30 4 (13.3) 0 0 0
Stomatitis 30 10 (33.3) 3 (10.0) 0 0
Febrile neutropenia 30 0 0 3 (10.0) 1 (3.3)
Skin rash 30 6 (20.0) 0 0 0
Arthralgia and myalgia 30 4 (13.3) 1 (3.3) 0 0
Perspiration 30 8 (26.7) 1 (3.3) 0 0
Dysgeusia 30 15 (50.0) 5 (16.7) 0 0
Nail changes 30 18 (60.0) 0 0 0
Hot flush 30 12 (40.0) 2 (6.7) 0 0
Depressive symptoms 30 8 (26.7) 1 (3.3) 0 0
Insomnia 30 8 (26.7) 0 0 0
Dyspepsia and abdominal pain 30 6 (20.0) 0 0 0
Sore throat and dysphagia 30 5 (16.7) 2 (6.7) 0 0
Chill 30 4 (13.3) 0 0 0
Increased urea 28 18 (64.3) 0 0 0
Increased potassium 30 4 (13.3) 0 0 0
Hypoproteinemia 23 4 (17.4) 0 0 0
Increased GGT 27 4 (14.8) 1 (3.7) 0 0
Increased GPT 27 4 (14.8) 0 0 0
Increased LDH 22 20 (90.9) 0 0 0
Anemia, day 21 25# 12 (48.0) 0 0 0
Anemia, day 7 21# 16 (76.2) 0 0 0
Leucopenia, day 7 26 5 (19.2) 4 (15.4) 10 (38.5) 4 (15.4)
Neutropenia, day 7 20 0 1 (5.0) 4 (20.0) 14 (70.0)
  1. Abbreviations: CTC, Common Terminology Criteria for Adverse Events; GGT, Gamma-Glutamyl-Transferase; GPT, Glutamat-Pyruvat-Transaminase; LDH, Lactate Dehydrogenase; #, five patients excluded due to preexisting anemia at inclusion.